Vitamin K: A structural basis for the design of novel neuroprotective agents?

Future Medicinal Chemistry

Volumn 5, Issue 8, 2013, Pages 857-860

  Chou, C James ^a   Inks, Elizabeth S ^a   Josey, Benjamin J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alzheimers disease; menaquinone; mitochondrial disease; MK 4; neuron; Parkinsons disease; UBIAD1; vitamin K; vitamin K2

Indexed keywords

DUROQUINONE; IDEBENONE; MENATETRENONE; VITAMIN K GROUP;

BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG DESIGN; FRIEDREICH ATAXIA; HUMAN; LEIGH DISEASE; NEUROPROTECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

DIMETHYLALLYLTRANSTRANSFERASE; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; VITAMIN K; VITAMIN K 2;

EID: 84878301592     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.70     Document Type: Review

References (20)

1. Dam H. The antihaemorrhagic vitamin of the chick. Biochem. J. 29(6), 1273-1285 (1935).
2. Shearer MJ. Vitamin K. Lancet 345(8944), 229-234 (1995).
3. Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb. Haemost. 100(4), 530-547 (2008).
4. Ferland G. Vitamin K and the nervous system: an overview of its actions. Adv. Nutr. 3(2), 204-212 (2012).
5. Thijssen HH, Vervoort LM, Schurgers LJ, Shearer MJ. Menadione is a metabolite of oral vitamin K. Br. J. Nutr. 95(2), 260-266 (2006).
6. Nakagawa K, Hirota Y, Sawada N et al. Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature 468(7320), 117-121 (2010).
7. Allison AC. The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease. Med. Hypotheses 57(2), 151-155 (2001).
8. Lindahl B, Eriksson L, Spillmann D, Caterson B, Lindahl U. Selective loss of cerebral keratan sulfate in Alzheimer's disease. J. Biol. Chem. 271(29), 16991-16994 (1996).
9. Presse N, Shatenstein B, Kergoat MJ, Ferland G. Low vitamin K intakes in communitydwelling elders at an early stage of Alzheimer's disease. J. Am. Diet. Assoc. 108(12), 2095-2099 (2008).
10. Huber AM, Davidson KW, O'Brien-Morse ME, Sadowski JA. Gender differences in hepatic phylloquinone and menaquinones in the vitamin K-deficient and -supplemented rat. Biochim. Biophys. Acta 1426(1), 43-52 (1999).
11. Kohlmeier M, Salomon A, Saupe J, Shearer MJ. Transport of vitamin K to bone in humans. J. Nutr. 126(4 Suppl.), 1192S-1196S (1996).
12. Mayeux R, Saunders AM, Shea S et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N. Engl. J. Med. 338(8), 506-511 (1998).
13. Vos M, Esposito G, Edirisinghe JN et al. Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. Science 336(6086), 1306-1310 (2012).
14. Josey BJ, Inks ES, Wen X, Chou CJ. Structure-activity relationship study of vitamin k derivatives yields highly potent neuroprotective agents. J. Med. Chem. 56(3), 1007-1022 (2013).
15. Erb M, Hoffmann-Enger B, Deppe H et al. Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I. PLoS ONE 7(4), e36153 (2012).
16. Enns GM, Kinsman SL, Perlman SL et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol. Genet. Metab. 105(1), 91-102 (2012).
17. Lynch DR, Willi SM, Wilson RB et al. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov. Disord. 27(8), 1026-1033 (2012).
18. Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J. Neurol. 259(2), 284-291 (2012).
19. Martinelli D, Catteruccia M, Piemonte F et al. EPI-743 reverses the progression of the pediatric mitochondrial disease - genetically defined Leigh Syndrome. Mol. Genet. Metab. 107(3), 383-388 (2012).
20. Sato T, Schurgers LJ, Uenishi K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr. J. 11